{
    "root": "1c6dff5c-3eab-49c1-8387-04a37a3fbbf5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PERJETA",
    "value": "20250507",
    "ingredients": [
        {
            "name": "PERTUZUMAB",
            "code": "K16AIQ8CTM"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 )",
    "contraindications": "For intravenous infusion only. Do not administer as an intravenous push or bolus. ( 2.5 ) HER2 testing:  Perform using FDA-approved tests by laboratories with demonstrated proficiency. ( 2.1 ) The initial PERJETA dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion. ( 2.3 ) MBC: Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and docetaxel every 3 weeks. ( 2.3 ) Neoadjuvant:  Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and chemotherapy preoperatively every 3 weeks for 3 to 6 cycles. ( 2.3 ) Adjuvant: Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and chemotherapy postoperatively every 3 weeks for a total of 1 year (up to 18 cycles). ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients [see Warnings and Precautions (5.4)]."
}